PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	3298.1001-000	10/072,611	
	FIRST NAMED INVENTOR	FILING DATE	
March 22, 2004	Brian Leyland-Jones	February 8, 2002	
(Use several sheets if necessary)	EXAMINER	CONFIRMATION NO.	GROUP
	C.J. Cheu	1456	1641

U.S. PATENT DOCUMENTS				
EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AA	5,830,672	11-03-1998	Wainer *et al.*

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES	NO
	AL	WO 00/55624 A2	09-21-2000	Brian Leyland-Jones		
	AM	EP 0921396 A2	06-09-1999	Pfizer Products Inc.		

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*	
AR	Tang, B.K., *et al.*, "Caffeine as a Metabolic Probe: Validation of its Use for Acetylator Phenotyping," *Clinical Pharmacology & Therapeutics*, 49(6): 648-657 (1991).
AS	Kroemer, H.K. and Eichelbaum, M., "'It's the Genes, Stupid'. Molecular Bases and Clinical Consequences of Genetic Cytochrome P450 2D6 Polymorphism," *Life Sciences*, 56(26): 2285-2298 (1995).
AT	Wong, P., *et al.*, "A Competitive Enzyme Linked Immunosorbent Assay for the Determination of *N*-acetyltransferase (NAT2) Phenotypes," *Journal of Pharmaceutical and Biomedical Analysis*, 13(9): 1079-1086 (1995).
AU	Wong, P., *et al.*, "Syntheses of Caffeine Metabolites Derivatives for Measuring CYP1A2 Activity by ELISA," Proceedings of the 90th Annual Meeting of the American Association for Cancer Research, 40:53 (1999).
AV	Wolf, C.R. and Smith, G., "Chapter 18. Cytochrome P450 CYP2D6," *Metabolic Polymorphisms and Susceptibility to Cancer*, 148:209-229 (1999).

EXAMINER	DATE CONSIDERED
C.J. Cheu	6/3/2004